La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Apyx Medical Crescita futura
Future criteri di controllo 1/6
Si prevede che Apyx Medical aumenterà gli utili e i ricavi rispettivamente del 19.1% e 11% all'anno, mentre si prevede che l'EPS crescerà del 30.7% all'anno.
Informazioni chiave
19.1%
Tasso di crescita degli utili
30.7%
Tasso di crescita dell'EPS
Medical Equipment crescita degli utili | 17.4% |
Tasso di crescita dei ricavi | 11.0% |
Rendimento futuro del capitale proprio | n/a |
Copertura analitica | Low |
Ultimo aggiornamento | 09 Aug 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 07We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed
Aug 01Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?
Jun 19Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Apr 18Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Mar 26Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)
Feb 16Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Sep 14Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?
Jun 07Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically
Mar 21Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation
Dec 14We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate
Aug 30Apyx Medical GAAP EPS of -$0.16 beats by $0.03, revenue of $10.3M misses by $0.26M
Aug 11Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck, chin
Jul 18Companies Like Apyx Medical (NASDAQ:APYX) Are In A Position To Invest In Growth
May 26Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
12/31/2026 | 61 | -17 | -6 | N/A | 3 |
12/31/2025 | 54 | -24 | -23 | N/A | 5 |
12/31/2024 | 51 | -25 | -22 | N/A | 4 |
6/30/2024 | 49 | -28 | -10 | -9 | N/A |
3/31/2024 | 50 | -23 | -10 | -10 | N/A |
12/31/2023 | 52 | -19 | -6 | -5 | N/A |
9/30/2023 | 50 | -15 | -8 | -8 | N/A |
6/30/2023 | 47 | -16 | -17 | -17 | N/A |
3/31/2023 | 44 | -21 | -18 | -18 | N/A |
12/31/2022 | 45 | -23 | -21 | -20 | N/A |
9/30/2022 | 49 | -19 | -17 | -16 | N/A |
6/30/2022 | 51 | -18 | -15 | -14 | N/A |
3/31/2022 | 52 | -16 | -14 | -13 | N/A |
12/31/2021 | 49 | -15 | -11 | -10 | N/A |
9/30/2021 | 43 | -15 | -12 | -12 | N/A |
6/30/2021 | 38 | -14 | -11 | -11 | N/A |
3/31/2021 | 31 | -15 | -11 | -11 | N/A |
12/31/2020 | 28 | -12 | -17 | -16 | N/A |
9/30/2020 | 25 | -16 | -19 | -18 | N/A |
6/30/2020 | 25 | -16 | -21 | -20 | N/A |
3/31/2020 | 28 | -16 | -22 | -21 | N/A |
12/31/2019 | 28 | -20 | -20 | -18 | N/A |
9/30/2019 | 26 | -18 | -35 | -33 | N/A |
6/30/2019 | 22 | -15 | -30 | -30 | N/A |
3/31/2019 | 19 | -14 | -25 | -25 | N/A |
12/31/2018 | 17 | -11 | -21 | -21 | N/A |
9/30/2018 | 14 | -10 | -2 | -2 | N/A |
6/30/2018 | 13 | -12 | -2 | -1 | N/A |
3/31/2018 | 5 | -15 | N/A | -2 | N/A |
12/31/2017 | 10 | -14 | N/A | -4 | N/A |
9/30/2017 | -12 | -19 | N/A | -5 | N/A |
6/30/2017 | -4 | -17 | N/A | -4 | N/A |
3/31/2017 | 37 | -4 | N/A | -3 | N/A |
12/31/2016 | 9 | -12 | N/A | -3 | N/A |
9/30/2016 | 35 | -5 | N/A | -3 | N/A |
6/30/2016 | 33 | -5 | N/A | -4 | N/A |
3/31/2016 | 31 | -6 | N/A | -6 | N/A |
12/31/2015 | 30 | 8 | N/A | -6 | N/A |
9/30/2015 | 29 | 4 | N/A | -5 | N/A |
6/30/2015 | 28 | 3 | N/A | -3 | N/A |
3/31/2015 | 27 | 4 | N/A | -1 | N/A |
12/31/2014 | 28 | -18 | N/A | 0 | N/A |
9/30/2014 | 26 | -18 | N/A | -2 | N/A |
6/30/2014 | 25 | -15 | N/A | -3 | N/A |
3/31/2014 | 24 | -16 | N/A | -3 | N/A |
12/31/2013 | 24 | -7 | N/A | -3 | N/A |
9/30/2013 | 24 | -2 | N/A | -1 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: APYX is forecast to remain unprofitable over the next 3 years.
Guadagni vs Mercato: APYX is forecast to remain unprofitable over the next 3 years.
Guadagni ad alta crescita: APYX is forecast to remain unprofitable over the next 3 years.
Ricavi vs Mercato: APYX's revenue (11% per year) is forecast to grow faster than the US market (8.8% per year).
Ricavi ad alta crescita: APYX's revenue (11% per year) is forecast to grow slower than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if APYX's Return on Equity is forecast to be high in 3 years time